Mark Leiser is a content strategist at Healio, specializing in hematology/oncology and cellular therapy. With a background in medical publishing since 2011, he focuses on various themes including oncology, immunotherapy, and wellness programs, aiming to provide valuable insights into medicine and healthcare. Leiser's work has been recognized in multiple prestigious awards, and he is featured in Healio.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Mark's coverage indicates a strong focus on healthcare and pharmaceuticals, particularly in the context of clinical trial data and scientific breakthroughs. He is most likely to be interested in pitches that provide access to exclusive data or insights related to new treatments for cancer, hemophilia, gene therapy, or other significant medical advancements.
Given Mark’s reliance on citing data, he may respond well to expert sources who can offer detailed analysis of clinical trial results or scientific developments in the mentioned fields. Pitches should emphasize the depth of expertise and ability to provide unique perspectives based on robust evidence.
It is important for potential contributors reaching out to Mark Leiser with relevant information regarding recent discoveries or groundbreaking research within these specialized areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mark Leiser
The addition of an off-the-shelf pooled stem cell product to a single unit of umbilical cord blood conferred favorable outcomes among people with hematologic malignancies, according to phase 2 trial results.Nearly all treated patients remained alive by data cutoff and none developed severe acute or chronic graft-versus-host disease.
By: Heather Biele, Mark Leiser
GLP-1 receptor agonists may help improve outcomes among women with breast cancer and chronic cardiometabolic diseases, results of a retrospective cohort study suggest.
By: Mark Leiser, Heather Biele
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Mark Leiser
CHICAGO — The cognitive effects men with advanced prostate cancer experience during treatment may vary based on the therapy they receive, according to randomized phase 2 trial results presented at ASCO Annual Meeting.An analysis of more than 100 men showed those randomly assigned to darolutamide (Nubeqa, Bayer) experienced significantly less cognitive decline over 24 weeks than those
By: Mark Leiser
The American Cancer Society updated its colorectal cancer screening guideline to reflect molecular-based screening tests that received regulatory approval in the past few years.The guideline — last updated in 2018 — now includes additional information about at-home multitarget stool tests. It also addresses a blood-based test that is administered in a physician’s office, though
By: Mark Leiser, Heather Biele
CHICAGO — The bispecific antibody linvoseltamab exhibited rapid clinical activity among patients with relapsed or refractory systemic light chain
By: Mark Leiser, Heather Biele
CHICAGO — The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND trial.
By: Heather Biele, Mark Leiser
CHICAGO — The first randomized trial to evaluate whether a multicancer early detection test using a blood sample could result in diagnosis at earlier stages yielded mixed results.
By: Mark Leiser, Heather Biele
CHICAGO — The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with localized high-risk
By: Mark Leiser, Heather Biele
CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.
